Skip to main content

Discover CIMERLI®

An FDA-approved treatment for retinal conditions1

Understanding your eye condition

If you've been diagnosed with

  • Wet age-related macular degeneration (wAMD)
  • Diabetic retinopathy and/or diabetic macular edema (DR, DME)
  • Myopic choroidal neovascularization (mCNV)
  • Macular edema following retinal vein occlusion (RVO)

you may be experiencing issues with your vision.

CIMERLI® is a prescription medicine for the treatment of patients with any of the conditions listed above.

The healthy eye consists of three essential layers to compose the eyeball. The outer dome-shaped layer contains the cornea. At the front of the middle layer, the choroid, is the iris. Within the inner layer, the vitreous gel houses the lens, macula, optic nerves and blood vessels.

Healthy eye

In these conditions, problems with eyesight can occur when:

Abnormal blood vessels grow in a part of the eye known as the retina

Healthy Blood Vessels

Healthy blood vessels

Abnormal Blood VesselsAbnormal Blood VesselsAbnormalities of blood vessels in the retina can include fluid leakage, blood vessel swelling, and abnormal vessel growth.

Abnormal blood vessels

View
Labels

OFF

Or, when these blood vessels leak fluid into an area of the retina called the macula

Healthy Macula

Healthy macula

Swollen MaculaSwollen MaculaThe macula can become swollen due to abnormal vessel growth and leaking fluid.

Swollen macula

View
Labels

OFF

One of the contributing factors that leads to the overgrowth of these blood vessels is the presence of a protein called vascular endothelial growth factor (VEGF). Medicine to help treat these conditions, called anti-VEGF treatment, works by blocking the VEGF protein.

CIMERLI® may be able to help

CIMERLI® is an anti-VEGF treatment that slows the growth of abnormal blood vessels in the eye.1

What is CIMERLI®?

CIMERLI® is an FDA-approved biosimilar that is interchangeable with Lucentis® (ranibizumab injection)2

CIMERLI® is a biosimilar—a type of biologic medicine that is highly similar to the FDA-approved biologic Lucentis®.3


CIMERLI® can be used to treat the same eye conditions as Lucentis®, and as an interchangeable biosimilar, it is expected to have the same effectiveness and safety, which makes it possible to be directly substituted for Lucentis®.1,3


With no clinically meaningful differences between the two medicines3, your doctor can choose to start or transition you to CIMERLI® without impacting your treatment.

Why are biosimilars important?4,5

Why are biosimilars important?4,5

Biosimilars were established to

  • Help reduce out-of-pocket & medication costs for patients
  • Make important treatments accessible to patients who need them
  • Potentially help reduce healthcare spending

all while maintaining the same quality, safety, and effectiveness of treatment.

What you can expect from CIMERLI®1,3

Your doctor has chosen to start or transition you to CIMERLI®. Here are some things you may find helpful to know:

Green checkmark

The same treatment approach

Both treatments are given as injections to the eye and are dosed the same way. Treatment is typically recommended monthly, but your doctor will determine a dosing schedule that is appropriate for you.

Green checkmark

The same way of working

Both treatments work the same way in the eye and are expected to produce the same clinical results.

Green checkmark

The same effectiveness & safety

CIMERLI® can be substituted for Lucentis without compromising treatment impact or safety. CIMERLI® was carefully reviewed and thoroughly evaluated by a rigorous FDA-approval process, and it is required to meet high FDA standards for consistent manufacturing to ensure medication quality and safety.

Financial support is available

Sandoz One Source® for CIMERLI® offers a range of financial assistance programs for patients who are prescribed CIMERLI®.

Co-Pay Savings Program

The Co-Pay Savings Program may cover out-of-pocket expenses associated with CIMERLI® and the injection procedure for eligible patients with commercial insurance*:

$0As little as

per dose of CIMERLI® including injection

with a maximum annual benefit of $16,000 per calendar year*

per dose of CIMERLI® including injection with a maximum annual benefit of $16,000 for drug costs per calendar year*

Talk to your doctor’s office to make sure you’re enrolled in Sandoz One Source so you can access all the program benefits

*Patient Drug and Injection Co-Pay Eligibility Criteria:

  • Be prescribed CIMERLI® for a medically appropriate purpose consistent with its FDA-approved labeling within 180 days of program enrollment
  • Have commercial (private or non-governmental) health insurance that covers the medication costs of CIMERLI®
  • Not covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Veterans Affairs, Department of Defense, or TRICARE
  • Not seek reimbursement from any third party, including payers, charitable foundations, or flexible spending accounts (FSAs ) or healthcare savings accounts (HSAs) for all or any part of the benefit received by Sandoz through this program
  • Other restrictions apply, see Terms & Conditions (opens in a new tab)
  • It is not valid for cash-paying patients or where prohibited by law
  • Co-Pay Savings Program subject to change or discontinuation without notice. This is not health insurance

Sandoz Patient Assistance (SPA)†

CIMERLI® may be available to you at no cost if you are uninsured or functionally underinsured.

Independent Foundation Support

Sandoz One Source may be able to help you find financial support through charitable foundations, or you can choose to contact these independent assistance foundations directly.

Call 1-844-4SANDOZ
(1-844-472-6369) Monday–Friday 8 AM to 8 PM ET for  any  questions  related  to  financial  support

†To be eligible for SPA assistance, you must:

  • Reside in the United States or a U.S. Territory
  • Have limited or no prescription insurance coverage
  • Meet income guidelines adjusted for household size, for the medication for which the patient is seeking assistance
  • Have a valid prescription for the Sandoz medication
  • Be treated by a licensed U.S. healthcare provider
  • Complete and sign consent form and, when applicable, provide income documentation

Learn more about CIMERLI®

The patient brochure includes more information about CIMERLI®, biosimilars, and the financial support that may be available to you.

Download the CIMERLI® Patient Brochure (opens in a new tab)
CIMERLI® patient brochureDownload the CIMERLI® Patient Brochure (opens in a new tab)

References:

  1. CIMERLI™ (ranibizumab-eqrn) prescribing information. Princeton, NJ: Sandoz, Inc.; 2024.
  2. Purple Book Database of Licensed Biological Products. U.S. Food and Drug Administration. https://purplebooksearch.fda.gov/faqs (opens in a new tab). Updated 2024. Accessed on June 4, 2024.
  3. Biosimilar and Interchangeable Products. https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices (opens in a new tab). Published October 23, 2017. Accessed on May 19, 2022.
  4. The U.S. Generic & Biosimilar Medicines Savings Report. Accessiblemeds.org. https://accessiblemeds.org/sites/default/files/2021-10/AAM-2021-US-Generic-Biosimilar-Medicines-Savings-Report-web.pdf (opens in a new tab). Published 2021. Accessed on February 22, 2022.
  5. Makurvet F. Biologics vs. small molecules: Drug costs and patient access. Med Drug Discov. 2021;9:100075.
    doi:10.1016/j.medidd.2020.100075

Important Safety Information

Important Safety Information

What Important Safety Information should I know about CIMERLI® (ranibizumab-eqrn)?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with ranibizumab products compared with patients who did not receive ranibizumab products. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by ranibizumab products
  • Severe inflammation of the veins in the retina, with or without blockage, usually with preexisting inflammation in the eye or after other treatments in the eye, have been reported with the use of ranibizumab products. You should tell your eye doctor if you have any changes in vision immediately. Your eye doctor may stop your treatment
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Important Safety Information

Important Safety Information

What Important Safety Information should I know about CIMERLI® (ranibizumab-eqrn)?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with ranibizumab products compared with patients who did not receive ranibizumab products. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by ranibizumab products
  • Severe inflammation of the veins in the retina, with or without blockage, usually with preexisting inflammation in the eye or after other treatments in the eye, have been reported with the use of ranibizumab products. You should tell your eye doctor if you have any changes in vision immediately. Your eye doctor may stop your treatment
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Important Safety Information

What Important Safety Information should I know about CIMERLI® (ranibizumab-eqrn)?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with ranibizumab products compared with patients who did not receive ranibizumab products. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by ranibizumab products
  • Severe inflammation of the veins in the retina, with or without blockage, usually with preexisting inflammation in the eye or after other treatments in the eye, have been reported with the use of ranibizumab products. You should tell your eye doctor if you have any changes in vision immediately. Your eye doctor may stop your treatment
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® full Prescribing Information (opens in a new tab).

Important Safety Information

Important Safety Information

What Important Safety Information should I know about CIMERLI® (ranibizumab-eqrn)?

  • You should not receive CIMERLI® if you have an infection in or around the eye or are allergic to CIMERLI® or any of its ingredients. CIMERLI® is a prescription medication given by injection into the eye, and it has side effects. CIMERLI® is not for everyone. Some patients using ranibizumab products have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away
  • Some patients have had increased eye pressure before and within 1 hour of an injection. Your eye doctor should check your eye pressure and eye health before and after your CIMERLI® injection
  • Uncommonly, patients using ranibizumab products have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with ranibizumab products compared with patients who did not receive ranibizumab products. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by ranibizumab products
  • Severe inflammation of the veins in the retina, with or without blockage, usually with preexisting inflammation in the eye or after other treatments in the eye, have been reported with the use of ranibizumab products. You should tell your eye doctor if you have any changes in vision immediately. Your eye doctor may stop your treatment
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, anemia, nausea, and cough
  • Reports of a tear in the outermost layer of the retina in patients with neovascular AMD (age-related macular degeneration) have been reported after treatment with ranibizumab products
  • CIMERLI® is for prescription use only

Call your doctor for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch (opens in a new tab).

For additional Safety Information, please talk to your doctor and see the CIMERLI® full Prescribing Information (opens in a new tab).

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Indications

Indications

Who is CIMERLI® for?

CIMERLI® is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (wAMD)
  • diabetic retinopathy and diabetic macular edema (DR and DME)
  • myopic choroidal neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

You are now
leaving CIMERLI.com

Sandoz is not responsible for the content of linked third-party websites. Please be aware that the privacy policies and terms of use on these sites are different from Sandoz policies.

Cancel Leave Site (opens in a new tab)

Please select which best describes you:

Healthcare Professional Patient or Caregiver

You are about to visit a website that contains clinical information created specifically for healthcare professionals.

If you are not a healthcare professional and would like to remain on the patient site, please click CANCEL.

Cancel Continue (opens in a new tab)